The Importance of the Comparator in Economic Evaluations

Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press, 2006 Goeree R, O’Brien B, Hunt R, et al. Economic evaluation of long-term management strategies for erosive oesophagitis. Pharmacoeconomics 1999 Dec; 16 (6): 679–97 Van Brabandt H, Camberlin C, Neyt M, et al. Cardiac resynchronisation therapy: a health technology assessment. Brussels: KCE, 2010 Bristow MR, Saxon LA, Boehmer J, et al. Cardiacresynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004 May 20; 350 (21): 2140–50 Neyt M, Thiry N, Ramaekers D, et al. Cost effectiveness of implantable cardioverter-defibrillators for primary prevention in a Belgian context. Appl Health Econ Health Policy 2008; 6 (1): 67–80 Van Brabandt H, Thiry N, Neyt M, et al. The implantable cardioverter defibrillator: a health technology assessment. Brussels: KCE, 2007 Lam SK, Owen A. Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials. BMJ 2007 Nov 3; 335 (7626): 925 Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006 Feb 23; 354 (8): 809–20 Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007 Jan 6; 369 (9555): 29–36 Hind D, Pilgrim H, Ward S. Questions about adjuvant trastuzumab still remain. Lancet 2007 Jan 6; 369 (9555): 3–5 Ward S, Pilgrim H, Hind D. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal. Health Technol Assess 2009; 13 Suppl. 1: 1–6 National Institute for Health and Clinical Excellence. Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer:NICE technology appraisal guidance. London: NICE, 2007 [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/TA107guidance.pdf [Accessed 2011 Sep 21] Huybrechts M, Hulstaert F, Neyt M, et al. Trastuzumab in early stage breast cancer: a health technology assessment. Brussels: KCE, 2006 Neyt M, Huybrechts M, Hulstaert F, et al. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium. Health Policy 2008 Aug; 87 (2): 146–59 Finnish Breast Cancer Group. The Synergism Or Long Duration (SOLD) study [ClinicalTrials.gov identifier NCT00593697]. US National Institutes of Health, Clinical-Trials.gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00593697?term=NCT00593697&rank=1 [Accessed 2011 Sep 21]